Axon Enterprise (NASDAQ:AXON) Price Target Lowered to $800.00 at The Goldman Sachs Group

Axon Enterprise (NASDAQ:AXON) had its price objective trimmed by The Goldman Sachs Group from $940.00 to $800.00 in a research note published on Wednesday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

AXON has been the topic of a number of other reports. JPMorgan Chase & Co. upped their price objective on shares of Axon Enterprise from $730.00 to $850.00 and gave the company an “overweight” rating in a research note on Thursday, July 17th. Craig Hallum raised shares of Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 price objective on the stock in a research note on Tuesday, August 5th. Piper Sandler reduced their price objective on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating on the stock in a research note on Wednesday. Northland Securities set a $800.00 price objective on shares of Axon Enterprise in a research note on Tuesday, August 5th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $855.00 price objective (up from $645.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Fifteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $813.07.

Axon Enterprise Price Performance

AXON stock opened at $639.53 on Wednesday. The company has a 50 day simple moving average of $726.40 and a 200 day simple moving average of $735.39. The stock has a market cap of $50.21 billion, a price-to-earnings ratio of 157.91, a P/E/G ratio of 29.49 and a beta of 1.41. Axon Enterprise has a 1 year low of $450.72 and a 1 year high of $885.91. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business had revenue of $710.64 million during the quarter, compared to analyst estimates of $704.83 million. During the same quarter last year, the company posted $1.45 earnings per share. The company’s revenue was up 30.6% compared to the same quarter last year. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts anticipate that Axon Enterprise will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, CAO Jennifer H. Mak sold 77 shares of the stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $760.00, for a total transaction of $58,520.00. Following the completion of the transaction, the chief accounting officer owned 15,003 shares in the company, valued at $11,402,280. This trade represents a 0.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction dated Tuesday, October 7th. The stock was sold at an average price of $713.74, for a total transaction of $7,137,400.00. Following the transaction, the chief executive officer owned 3,033,982 shares of the company’s stock, valued at $2,165,474,312.68. This represents a 0.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 59,932 shares of company stock valued at $45,115,616 in the last three months. 4.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Axon Enterprise

A number of large investors have recently modified their holdings of the company. Plato Investment Management Ltd boosted its position in shares of Axon Enterprise by 79.4% in the third quarter. Plato Investment Management Ltd now owns 1,195 shares of the biotechnology company’s stock valued at $851,000 after acquiring an additional 529 shares during the period. Azzad Asset Management Inc. ADV bought a new position in shares of Axon Enterprise in the third quarter valued at approximately $613,000. Smartleaf Asset Management LLC boosted its position in shares of Axon Enterprise by 112.4% in the third quarter. Smartleaf Asset Management LLC now owns 480 shares of the biotechnology company’s stock valued at $344,000 after acquiring an additional 254 shares during the period. Canada Post Corp Registered Pension Plan boosted its position in shares of Axon Enterprise by 18.7% in the third quarter. Canada Post Corp Registered Pension Plan now owns 1,460 shares of the biotechnology company’s stock valued at $1,045,000 after acquiring an additional 230 shares during the period. Finally, State of Michigan Retirement System boosted its position in shares of Axon Enterprise by 5.5% in the third quarter. State of Michigan Retirement System now owns 21,200 shares of the biotechnology company’s stock valued at $15,214,000 after acquiring an additional 1,100 shares during the period. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.